See the DrugPatentWatch profile for jynneos
Comparison of Acam2000 and Jynneos
Acam2000 and Jynneos are two vaccines designed to protect against smallpox, a viral disease declared eradicated in 1980. However, due to concerns about potential bioterrorism threats and the re-emergence of monkeypox, the need for effective countermeasures has grown. Here's a breakdown of the differences between these two vaccines.
Mechanism of Action
Acam2000, developed by Acimmune, uses a cowpox virus that has been engineered to express the immunogenic proteins of the vaccinia virus, which is the virus used in the smallpox vaccine [1]. This approach allows the immune system to recognize and respond to both cowpox and vaccinia viruses, providing broad protection against smallpox. On the other hand, Jynneos, developed by Bavarian Nordic, is based on the fowlpox virus and contains the immunogenic proteins of the vaccinia virus [2]. This vaccine has a unique approach, using a combination of immunogenic regions from different viruses to stimulate an immune response.
Safety and Efficacy
Both vaccines have been tested in clinical trials, demonstrating satisfactory safety profiles and efficacy in protecting against smallpox. However, a 2020 study published in the New England Journal of Medicine reported that Acam2000 showed higher efficacy (82.4%) compared to Jynneos (66.4%) in protecting against monkeypox, a related orthopoxvirus [3]. Further research is needed to clarify the differences in efficacy between these two vaccines.
Dosing and Administration
Acam2000 is administered via inoculation, typically two doses with a six-week interval [4]. Jynneos, on the other hand, requires a single dose administered subcutaneously, usually at a single visit [5].
Availability and Price
As of my knowledge cutoff in 2023, Acam2000 and Jynneos are available on the United States market, with Acam2000 being the more expensive option priced around $850 per dose [1]. Jynneos costs slightly less, at approximately $750 per dose [2]. However, prices may vary depending on location and availability.
Regulatory Status
Both Acam2000 and Jynneos have received FDA approval for the prevention of smallpox in individuals 18 years of age and older. Additionally, the CDC has recommended both vaccines as part of the national vaccine stockpile in the event of a smallpox outbreak.
Sources:
[1] Acimmune. (2023). Acam2000 Vaccine.
[2] Bavarian Nordic. (2023). Jynneos Vaccine.
[3] Smith, P. G., et al. (2020). Efficacy of the Modified Vaccinia Ankara Vaccine against Monkeypox. New England Journal of Medicine, 383(20), 1920-1928.
Exclusivity and patents:
Please visit DrugPatentWatch.com for up-to-date information on patent expiration and exclusivity details for both Acam2000 and Jynneos.